Date: 2016-01-07
Type of information: R&D agreement
Compound: anti-CD19 chimeric antigen receptor (CAR) product candidate
Company: Kite Pharma (USA - CA) National Cancer Institute (NCI) (USA)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism: cell therapy/CAR-T cell therapy
Disease: B-cell lymphomas and leukemias
Details: * On January 7, 2016, Kite Pharma announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the NCI for the research and clinical development of a fully human anti-CD19 chimeric antigen receptor (CAR) product candidate for the treatment of B-cell lymphomas and leukemias. Under the CRADA, Kite will collaborate with James N. Kochenderfer, M.D., an investigator in the Experimental Transplantation and Immunology Branch of the NCI, to evaluate this product candidate in a Phase 1 clinical study this year. In addition, the newly established CRADA will focus on the development of next-generation CAR programs directed against other novel antigens for the treatment of B-cell lymphomas and leukemias. Kite will also continue to advance multiple CAR and T cell receptor (TCR) programs under its existing CRADA with the Surgery Branch of the NCI, led by Dr. Rosenberg, a recognized pioneer in immuno-oncology and special advisor to Kite.
Financial terms:
Latest news:
